At the close, AK Medical (01789) rose nearly 5%, and as of the press release, it rose 4.5% to HKD 4.64, with a turnover of HKD 10.9521 million.
As informed by the Wisdom Finance app, AK Medical (01789) rose nearly 5% at the close, and as of the press release, it rose 4.5% to HKD 4.64, with a turnover of HKD 10.9521 million.
China Securities Co., Ltd. stated that looking forward to Q3 and the second half of the year, the joint procurement renewal results began to be implemented successively around the end of June. In the short term, the joint procurement renewal landing will boost AK prices, and the price difference between manufacturers will shrink, which is bullish for domestic leading companies. In the medium and long term, the penetration rate of joint replacement surgery is still relatively low in China, and under the trend of aging population, the joint industry still has a large growth space. The company has a first-mover advantage in the 3D printing field, and its innovative joint products are expected to quickly gain momentum. At the same time, after the joint procurement period, the company accelerates the expansion of overseas markets, and its self-owned products are competitive in emerging markets, with the proportion of overseas income continuously increasing, and are expected to become the company's new performance growth driver in the future.
CITIC Securities believes that there are a large number of joint disease patients in China, and there is still room for improvement in the surgical penetration rate. The volume of joint replacement surgery has gradually increased in recent years, but there is still a certain gap compared to developed countries such as Europe and the United States. The joint procurement of the AK further releases clinical demand. In the long run, joint procurement will lead to a significant reduction in the total cost of clinical treatment of joint diseases, further release clinical demand, and promote the sustained increase of surgical volume.